Revon has partnered with a pharmaceutical company to support a natural history study that will begin recruiting later this year in the United Kingdom. This study will enroll patients in an orphan disease indication. There is an incomplete understanding of how the disease progresses over time and how patients experience this is in the form of signs and symptoms. Revon will provide a mobile platform and wearable device integration to capture the relevant patient outcome measures.

For more information, contact us.